Arimidex (ZD1033): a selective, potent inhibitor of aromatase in post-menopausal female volunteers
1996

Effects of Arimidex on Oestradiol in Post-Menopausal Women

Sample size: 22 publication Evidence: moderate

Author Information

Author(s): RA Yates, M Dowsett, GV Fisher, A Selen, PJ Wyld

Primary Institution: Zeneca Pharmaceuticals

Hypothesis

What is the pharmacokinetic profile and effect of Arimidex on oestradiol levels in post-menopausal women?

Conclusion

Arimidex significantly reduces serum oestradiol levels in post-menopausal women without affecting other steroid hormones.

Supporting Evidence

  • Mean serum oestradiol concentrations decreased by approximately 70% compared to placebo by 48 hours after the first dose.
  • After multiple doses, oestradiol concentrations were suppressed by 80% compared to baseline.
  • 1.0 mg of ZD1033 was found to be the minimal dose required for maximal suppression of oestradiol.

Takeaway

Arimidex is a medicine that helps lower a hormone called oestradiol in women who have stopped having periods, which can help treat breast cancer.

Methodology

Two randomized, double-blind, placebo-controlled studies were conducted with healthy post-menopausal women to assess the effects of Arimidex on oestradiol levels.

Limitations

The studies had a small sample size and were limited to healthy post-menopausal women.

Participant Demographics

Healthy post-menopausal female volunteers aged 45 to 62 years.

Statistical Information

P-Value

0.001

Confidence Interval

(0.52, 2.30)

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication